Lexicon Pharmaceuticals, Inc. (LXRX) Announces Commenced Phase 2 Clinical Trials
Lexicon Pharmaceuticals, Inc. (LXRX) has announced that the company has commenced Phase 2a clinical trial for their LX6171 drug, a prevalent oral drug candidate. This drug will treat cognitive impairment, often associated with disorders such as Alzheimer's disease, schizophrenia, and vascular dementia. Detailed information about this clinical trial will be available shortly. Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human diseases. Lexicon has various clinical programs underway, for such areas as irritable bowel syndrome, cognitive disorders, and rheumatoid arthritis. Since Lexicon's formation, the company has discovered more than 100 promising drug targets,…